SPOTLIGHT -
Dr. Tolba on the Use of Afatinib in NRG1-Mutated in Lung Adenocarcinoma
Khaled A. Tolba, MD, MBBCh, discusses the use of afatinib in NRG1 fusion–positive lung adenocarcinoma.
Read More
Dr. Tolba on Targeting NRG1 Fusions With Afatinib
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses the potential to target NRG1 fusion–positive lung adenocarcinoma with afatinib (Gilotrif).
Dr. Tolba on Targeting NRG1 Fusions in NSCLC
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
